Related Experiment Video
Updated: Mar 29, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Insulin pumps: Beyond basal-bolus.
Richard Millstein1, Nancy Mora Becerra2, Jay H Shubrook3
1Department of Endocrinology, University of Colorado, Denver, CO, USA.
Cleveland Clinic Journal of Medicine
|December 15, 2015
Summary
Insulin pumps offer advanced diabetes management, improving insulin dosing accuracy and flexibility. They are a preferred treatment for type 1 and type 2 diabetes patients requiring basal-bolus insulin therapy.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Biomedical Engineering
Background:
- Insulin pumps represent a significant advancement in diabetes care.
- They offer improved accuracy, flexibility, and safety for insulin delivery.
- Basal-bolus insulin therapy is crucial for many individuals with diabetes.
Purpose of the Study:
- To review the fundamental principles of insulin pump operation.
- To identify patient populations who benefit from insulin pump therapy.
- To outline management strategies for inpatients and outpatients using insulin pumps.
Main Methods:
- Literature review on insulin pump technology and clinical application.
- Analysis of benefits, safety, and efficacy data for insulin pump users.
- Examination of inpatient and outpatient management protocols.
Main Results:
- Insulin pumps enhance the ease and precision of insulin dosing.
- They provide significant flexibility, safety, and efficacy for basal-bolus therapy.
- Preferred treatment for type 1 diabetes and many type 2 diabetes patients.
Conclusions:
- Insulin pump therapy is a cornerstone of modern diabetes management.
- Understanding pump function and management is key for healthcare providers.
- This review provides essential information for optimizing insulin pump use in diverse patient settings.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
01:27Insulin Formulations: Types and Delivery
1.1K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.1K
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.9K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.9K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
3.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
3.1K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:15Diabetes: Management and Pharmacotherapy
1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K